SUMMARY During a control infusion noradrenaline and alcohol each provoked carcinoid flushing in four of five patients and pentagastrin in two of five patients. When tetradecapeptide somatostatin was infused on another day no patient flushed at any time, even when 16 jig of either noradrenaline or pentagastrin were administered. Carcinoid flushing was not associated with release of gastrin or any of the other vasoactive or postprandially released gut regulatory peptides measured. In a sixth patient with severe prolonged carcinoid flushing, subcutaneous Des AA' 2.4 5, 12 D Trp8 somatostatin markedly reduced the incidence and severity of flushing for two days. Somatostatin is thus a potent inhibitor of carcinoid flushing, but no evidence has been found for the gut hormones measured to be mediators of flushing.
patient with severe prolonged carcinoid flushing, subcutaneous Des AA' 2.4 5, 12 D Trp8 somatostatin markedly reduced the incidence and severity of flushing for two days. Somatostatin is thus a potent inhibitor of carcinoid flushing, but no evidence has been found for the gut hormones measured to be mediators of flushing.
Somatostatin is a 14 aminoacid polypeptide ( Fig. 1 ) which was initially isolated in the hypothalamus as growth hormone release inhibitory hormone ' but subsequently has been demonstrated to be present in the D cell in man throughout the gastrointestinal tract and pancreas and in the C cell of the thyroid.2 Infusion studies have shown that it has widespread effects in inhibiting plasma concentrations of many anterior pituitary, gastrointestinal, and pancreatic hormones and it also causes a reduction in pancreatic, biliary, and gastrointestinal secretions.3 In man somatostatin has a half-life of about three minutes4 and, in view of its therapeutic potential, attempts have been made to synthesise analogues which are long acting when given subcutaneously.5 A recent report in three patients with the carcinoid syndrome suggested that tetradecapeptide somatostatin could prevent stimulated flushing.6 As pentagastrin stimulated carcinoid flushing in these patients and plasma gastrin concentrations are known to rise after a meal (a common flush-provoker), it was suggested that gastrin might be a mediator of the X / Cases 1-5 were studied after fasting overnight on two mornings 48 hours apart. A thermistor to monitor continuously skin temperature was attached to the forehead. An intravenous cannula was inserted into an antecubital fossa vein in both arms. Basal blood samples were collected (-20, -10, zero minutes). The infusion was started after the zero blood sample: on the first day this contained 0.9 g% (w/v) sodium chloride and 2 g% (w/v) human albumin (infusion rate 1 1 ml/minute) and on the second study day somatostatin (70 pmol/kg/min) was added to the infusate. After 20 minutes' infusion the patients were given serial intravenous bolus injections of noradrenaline (dose range 1 0-16-0 ,ug/min) and pentagastrin (dose range 0-5-16.0 gg/min) and oral alcohol (40 ml sherry). If no flush had occurred five minutes after an injection of noradrenaline or pentagastrin, the dose was doubled and the test repeated to a maximum of 16 jig. A flush was defined as the development of marked cutaneous erythema of the head and neck associated with a rise in skin temperature of at least 0 6°C, a rise in pulse rate of at least 10 per minute, and a fall in systolic blood pressure of at least 10 mmHg.
Basal blood samples for plasma glucose and gut peptide measurement were taken before each new substance was given, at the beginning, middle, and end of each flush and, if no flush were induced, three minutes after 16 gg of pentagastrin or noradrenaline or the alcohol had been given (it was found that flushing started approximately three minutes after an oral or intravenous stimulus was given). The plasma hormone samples were collected into heparinised tubes containing 400 Kallikrein-inactivating units of aprotinin (Trasylol)/ml blood added, centrifuged immediately, and stored until radioimmunoassay.
Plasma glucose was measured by autoanalyser. Previously described radioimmunoassays were used for the measurement of plasma gastrin,7 vasoactive intestinal polypeptide,8 neurotensin,9 pancreatic polypeptide,'°motilin," insulin,'2 gastric inhibitory polypeptide,'3 glucagon, and enteroglucagon. [14] [15] [16] Patient 6 was taken off her medication for two days and then assessed for a control day (day 1 Table 2 ). The somatostatin did gzot prevent the systemic effects of the larger doses of noradrenaline or pentagastrin. When somatostatin was infused none of the patients had any abnormal symptoms and no significant change in blood pressure or pulse occurred. In patient 2, withdrawal of somatostatin was associated with a mild flush lasting eight minutes.
Fasting plasma glucose and gut peptide concentrations are shown in Table 3 and are all within the normal range. Plasma glucose and peptide concentrations did not change at any time during the provoked flushing attacks on the control infusion day. During the somatostatin infusions the mean concentrations of all fell.
The response of case 6 to subcutaneous Des AA', 2, 4, 5. 12D Trp8 somatostatin is shown in Fig. 2 . Severe prolonged spontaneous facial, trunk, and limb flushing with lacrimation occurred on the control days 1 and 4. When the nonapeptide somatostatin analogue was given on days 2 and 3, the severity and duration of flushing were much reduced with facial involvement only and lacrimation disappeared. The patient experienced no side-effects and the nonapeptide somatostatin analogue appeared superior in this short-term study to her previous oral quadruple therapy (Table 1) .
Discussion
This study confirms the previous observation that intravenous tetradecapeptide somatostatin is a highly effective inhibitor of pentagastrin induced carcinoid flushing.6 In addition it has been demonstrated that somatostatin also inhibits spontaneous flushing and flushing induced by noradrenaline and alcohol. No side effects were seen apart from one patient who had a mild episode of 'rebound' flushing on stopping the infusion. In another unreported patient we have observed a major 'rebound' effect with diarrhoea, asthma, and prostration for 30 minutes. Davis et al. have reported a patient with the carcinoid syndrome whose secretory diarrhoea and small intestinal water, chloride, and sodium absorption improved during a 48 hour intravenous somatostatin infusion. 8 The study using the subcutaneous nonapeptide somatostatin analogue shows that this analogue also helps unprovoked flushing. Somatostatin may thus have a future role as a symptomatic treatment for several aspects of the carcinoid syndrome.
The provocation of carcinoid flushing by numerous Gastric inhibitory polypeptide (pmol/l) 100± 1.5
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Glucagon (pmolfl) It has been suggested that tumour kallikrein release with subsequent bradykinin formation may be the humoral mechanism of carcinoid flushing but the case is not proven.20 In some patients with gastric carcinoids histamine may have a role to play in the production of the 'geographical' flushing and a combination of HI and H2 blocking agents may be effective in these patients.2' A number of peptides including pancreatic polypeptide, neurotensin, enteroglucagon, motilin, and substance P have been demonstrated to be present in carcinoid tumours. Infusion studies have shown that vasoactive intestinal polypeptide, neurotensin, and substance P are vasoactive peptides and gastric inhibitory polypeptide, pancreatic polypeptide, neurotensin, enteroglucagon, motilin, insulin, and pancreatic glucagon are all released after a meal.3 It therefore seemed possible that one or more of these peptides might be flush provokers or mediators. This study has provided no evidence for this hypothesis but clearly demonstrates that some part of the presumed biochemical cascade of carcinoid flushing is somatostatin sensitive, and, from the spectrum of its effects, it seems quite likely that somatostatin is preventing the release of pharmacologically active materials from the tumour cell, whatever the provoking agent.
The search for long-acting and specific somatostatin analogues continues. This study shows that subcutaneous Des AAI 2, 4, 5, 12D Trp8 somatostatin has a prolonged duration of action in preventing carcinoid flushing without side-effects. The prolonged duration of action presumably occurs because of slow release of the hydrophobic molecule from subcutaneous tissues. An effective subcutaneous injection given once or twice daily has obvious advantages over continuous intravenous infusion. Somatostatin and its analogues might be particularly useful for the treatment of carcinoid 'crises' and during surgery to prevent the severe bronchoconstriction and hypotension which may occur.
